This trial is conducted in Africa, Asia, Europe and South America. This trial is designed to show the effect of treatment with liraglutide added to existing glimepiride and metformin combination therapy and to compare it with the effects of insulin glargine added to combination therapy of glimepiride and metformin.

Inclusion Criteria:

• Type 2 diabetes
• Treatment with oral anti-diabetic drugs for at least 3 months
• HbA1c: 7.5-10.0 % (both incl.) in subjects on OAD monotherapy. 7.0-10.0 % (both incl.) in subjects on OAD combination therapy.
• Body Mass Index (BMI) less than or equal to 45 kg/m2

Exclusion Criteria:

• Treatment with insulin within the last 3 months
• Treatment with any drug that could interfere with the glucose level
• Any serious medical condition
• Females who are pregnant, have intention of becoming pregnant or are breastfeeding